Sleep behavior of infants with infantile hemangioma treated with propranolol—a cohort study
Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function. In this cohort study, we objectively investigate the sleep behavior of infants with infantile hemangiomas on pr...
Gespeichert in:
Veröffentlicht in: | European journal of pediatrics 2021-08, Vol.180 (8), p.2655-2668 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function. In this cohort study, we objectively investigate the sleep behavior of infants with infantile hemangiomas on propranolol compared to a healthy, untreated control group. Sleep of propranolol-treated infants and controls was investigated using ankle actigraphy and a 24-h diary for 7–10 days at ages 3 and 6 months. The main outcome measures were the
Number of Nighttime Awakenings
and
Sleep Efficiency
. The main secondary outcome measures included
24-hour Total Sleep
, daytime sleep behavior, and parent-rated infant sleep quality and behavioral development based on the Brief Infant Sleep Questionnaire (BISQ) and the age-appropriate Ages-and-Stages Questionnaire (ASQ), respectively. Fifty-four term-born infants were included in each cohort. No group difference in any investigated parameter was seen at age 3 months. At age 6 months, the propranolol group exhibited a decrease in
Sleep Efficiency
and a trend towards an increased
Number of Nighttime Awakenings
compared to the control group. Treated infants at 6 months also had shorter daytime waking periods.
24-hour Total Sleep
was unaffected by propranolol. No negative impact of propranolol on subjective sleep quality and behavioral development was noted.
Conclusion
: Propranolol exerts a measurable yet mild impact on objectively assessed infants’ sleep measures. Behavioral developmental scores were unaffected. Our results support propranolol as first-line therapy for complicated infantile hemangiomas.
What is Known:
• Sleep disorders are frequently reported in infants with infantile hemangiomas treated with propranolol and often lead to treatment discontinuation.
• Investigations of the sleep pattern in this patient group using objective measures are lacking.
What is New:
• The sleep pattern of propranolol-treated infants is assessed using actigraphy and a 24-h sleep diary and compared to healthy, untreated controls.
• Propranolol leads to a decreased sleep efficiency at night and an increased demand of daytime sleep, yet effects are mild overall. |
---|---|
ISSN: | 0340-6199 1432-1076 |
DOI: | 10.1007/s00431-021-04147-3 |